Zhixiang Cheng

180 Fenglin Road
Zhongshan, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 10 publications

The efficacy, safety, and rationale of orelabrutinib combined with obinutuzumab (O2) as a first-line systemic treatment for marginal zone lymphoma.

The efficacy, safety, and rationale of orelabrutinib combined with obinutuzumab (O2) as a first-line systemic treatment for marginal zone lymphoma.

Journal: Blood cancer journal

Published: March 22, 2026

Pola-R-CHP performed well in first-line Polarix trial-ineligible and IPI 0-1 DLBCL patients : Article type: research.

Pola-R-CHP performed well in first-line Polarix trial-ineligible and IPI 0-1 DLBCL patients : Article type: research.

Journal: Annals of hematology

Published: June 24, 2025

Effectiveness and Safety of Polatuzumab Vedotin Plus an Anti-CD20 Monoclonal Antibody (Rituximab or Obinutuzumab) and Zanubrutinib in Relapsed/Refractory Diffuse Large B-Cell Lymphoma.

Effectiveness and Safety of Polatuzumab Vedotin Plus an Anti-CD20 Monoclonal Antibody (Rituximab or Obinutuzumab) and Zanubrutinib in Relapsed/Refractory Diffuse Large B-Cell Lymphoma.

Journal: Cancer medicine

Published: May 18, 2025

MaskMol: knowledge-guided molecular image pre-training framework for activity cliffs with pixel masking.

MaskMol: knowledge-guided molecular image pre-training framework for activity cliffs with pixel masking.

Journal: BMC biology

Published: February 19, 2025

Polatuzumab Vedotin, zanubrutinib and rituximab (Pola-ZR) achieved rapid and deep response in untreated frail and elderly DLBCL.

Polatuzumab Vedotin, zanubrutinib and rituximab (Pola-ZR) achieved rapid and deep response in untreated frail and elderly DLBCL.

Journal: Annals of hematology

Published: August 18, 2024

A prognostic model incorporating inflammatory cells and cytokines for newly diagnosed multiple myeloma patients.

A prognostic model incorporating inflammatory cells and cytokines for newly diagnosed multiple myeloma patients.

Journal: Clinical and experimental medicine

Published: October 23, 2022

The paradoxical prognostic role of 1q21 Gain/Amplification in multiple myeloma: every coin has two sides.

The paradoxical prognostic role of 1q21 Gain/Amplification in multiple myeloma: every coin has two sides.

Journal: Leukemia & lymphoma

Published: June 11, 2020

A single center experience: rituximab plus cladribine is an effective and safe first-line therapy for unresectable bronchial-associated lymphoid tissue lymphoma.

A single center experience: rituximab plus cladribine is an effective and safe first-line therapy for unresectable bronchial-associated lymphoid tissue lymphoma.

Journal: Journal of thoracic disease

Published: May 20, 2017

Appropriate Clinical Strategies for Breast Cancer Coexisting with Acute Myeloid Leukemia in the Genomic-Molecular Era: A Case Report.

Appropriate Clinical Strategies for Breast Cancer Coexisting with Acute Myeloid Leukemia in the Genomic-Molecular Era: A Case Report.

Journal: Breast care (Basel, Switzerland)

Published: May 31, 2016

HBsAg is an independent prognostic factor in diffuse large B cell lymphoma patients in rituximab era: result from a multicenter retrospective analysis in China.

HBsAg is an independent prognostic factor in diffuse large B cell lymphoma patients in rituximab era: result from a multicenter retrospective analysis in China.

Journal: Medical oncology (Northwood, London, England)

Published: December 07, 2013

Showing 1-10 of 10

Last Updated: 09/26/2026